Eli Lilly and Company (LLY) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Jaypirca, a non-covalent Bruton's tyrosine kinase inhibitor, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia who have been previously treated with a BTK inhibitor. The European Commission's decision is expected in the next one to two months.
The company noted that Jaypirca has previously received a conditional marketing authorization by the EMA for the treatment of adult patients with relapsed or refractory mantle cell lymphoma who have been previously treated with a BTK inhibitor.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.